StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
SIMA

SIM Acquisition Corp. I

SIMAW Nasdaq Blank Checks EDGAR ↗
$0.16
-0.04 -20.00%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$1.07M
Revenue (TTM) ⓘ
—
Net income (TTM) ⓘ
$6.68M
EPS (TTM) ⓘ
—
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
—
Cash ⓘ
$260K
Total assets ⓘ
$6.45M
Gross margin ⓘ
—
52-week range ⓘ
$0.16 – $0.16

AI briefing

from the latest 10-K, 10-Q and 8-K events

SIM Acquisition Corp. I is a blank check company focused on healthcare industry business combinations, with no target selected yet.

What they do

SIM Acquisition Corp. I is a Cayman Islands exempted company formed to effect a business combination, focusing on companies in the healthcare industry. It completed its IPO in July 2024, raising $230 million in gross proceeds, and holds those funds in a trust account. The company has not selected any business combination target.

Revenue drivers

  • Interest income on trust account — The company earns interest on the $230 million held in the trust account, which is its primary source of income.

Recent performance

For fiscal year 2025, the company reported net income of $8.8 million, up from $4.7 million in 2024. Operating cash flow was negative $631,658 in 2025, improving from negative $843,935 in 2024. As of June 30, 2026, total assets were $6.4 million, total liabilities $1.1 million, and cash and equivalents were $260,436, with negative shareholder equity of $693,323.

Strategy

The company intends to use cash from the IPO and private placement, plus proceeds from future share sales, debt, or securities issued to target owners, to complete a business combination. It focuses on healthcare companies. Management is actively searching for a target, and the deadline for completing a business combination is July 12, 2027 (36 months from the IPO close).

Risks

  • Failure to complete business combination — If no business combination is completed by July 12, 2027, the company will redeem all public shares and wind down.
  • Dilution from share issuance — Issuing additional shares in a business combination could significantly dilute the equity interest of public investors.
  • Debt financing risks — Incurring debt could lead to default, acceleration of obligations, or restrictions on financial flexibility.
  • Key executive and board changes — The company underwent a sponsor acquisition in January 2026, leading to the resignation of former executives and the appointment of new leadership.

Outlook

Management continues to evaluate potential target companies in the healthcare industry. The company has until July 12, 2027, to complete a business combination, with an extension period subject to shareholder approval. If the deadline is missed, the company will redeem public shares and cease operations.

Recent SEC filings

40 most recent
Annual, quarterly & current reports
Other filings
SCHEDULE 13G/A Sep 4, 2026
SCHEDULE 13G/A Aug 14, 2026
SCHEDULE 13G/A Aug 12, 2026
SCHEDULE 13G/A Aug 11, 2026
SCHEDULE 13G/A Jun 5, 2026
SCHEDULE 13D May 15, 2026
SCHEDULE 13G/A May 15, 2026
SCHEDULE 13G/A May 15, 2026
SCHEDULE 13G/A Apr 27, 2026